华润双鹤(600062) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥2,835,466,240.22, representing a 2.26% increase compared to ¥2,738,700,207.28 in the same period last year[6] - Net profit attributable to shareholders was ¥416,107,568.49, an increase of 11.00% from ¥372,438,512.01 year-on-year[6] - Basic earnings per share rose to ¥0.4075, reflecting an 11.01% increase from ¥0.3648 in the previous year[7] - Net profit for Q1 2024 was ¥494,441,260.82, compared to ¥462,639,666.58 in Q1 2023, indicating an increase of 6.86%[21] - Total profit for Q1 2024 reached ¥510.42 million, an increase of 10.3% compared to ¥462.88 million in Q1 2023[23] - Net profit attributable to shareholders of the parent company was ¥416.11 million, up 10.9% from ¥374.88 million in the same period last year[23] - Total comprehensive income for Q1 2024 was ¥404.71 million, compared to ¥383.42 million in Q1 2023, reflecting a 5.6% increase[23] Cash Flow and Assets - The net cash flow from operating activities surged by 150.61%, reaching ¥301,694,826.87, attributed to an increase in sales receipts and a decrease in procurement expenses[7][10] - Cash flow from operating activities generated ¥301.69 million, significantly higher than ¥120.39 million in Q1 2023, marking a 150.3% increase[25] - Cash and cash equivalents at the end of Q1 2024 were ¥3.54 billion, compared to ¥2.28 billion at the end of Q1 2023, representing a 55.2% increase[26] - As of March 31, 2024, the company's cash and cash equivalents amounted to RMB 3,648,333,171.15, an increase from RMB 3,457,023,212.09 at the end of 2023, reflecting a growth of approximately 5.5%[16] - Total current assets of RMB 7,866,918,834.27 as of March 31, 2024, compared to RMB 7,638,486,881.28 at the end of 2023, showing an increase of approximately 3.0%[16] Investments and Acquisitions - The company acquired 89.681% of Guizhou Tianan Pharmaceutical Co., Ltd. for ¥260,355,691.22, leading to a restatement of the previous year's financial data[8] - The company completed the acquisition of 100% equity in China Resources Zizhu Pharmaceutical Co., Ltd., with a payment of RMB 2,180,817,170, which is 70% of the total transaction amount[15] - The company plans to consolidate the financial statements of China Resources Zizhu starting from April 2024, following the completion of the acquisition[15] - Long-term equity investments rose to ¥354,342,815.29 from ¥341,574,290.42, an increase of 3.25%[19] Liabilities and Equity - Total liabilities decreased to ¥3,475,143,024.94 from ¥3,641,187,325.63, a reduction of 4.56%[19] - The company's equity attributable to shareholders increased to ¥11,515,832,857.47 from ¥11,090,411,326.34, reflecting a rise of 3.83%[19] - Total assets at the end of the reporting period were ¥15,679,093,603.46, a 1.61% increase from ¥15,430,959,899.25 at the end of the previous year[7] Research and Development - R&D expenses increased to ¥130,334,326.03 in Q1 2024 from ¥111,343,291.19 in Q1 2023, marking a growth of 17.06%[21] Other Financial Metrics - The weighted average return on equity increased to 3.68%, up by 0.13 percentage points compared to the previous year[7] - The company reported non-recurring gains totaling ¥18,286,626.34 for the period[9] - The company reported a significant increase in investment income, which reached ¥12,768,524.87 in Q1 2024, compared to ¥3,896,620.38 in Q1 2023, a growth of 227.06%[21] - Operating costs for Q1 2024 were ¥2,345,151,699.63, up from ¥2,313,482,304.10 in Q1 2023, reflecting a rise of 1.37%[21] - The company reported a decrease in other comprehensive income, with a net amount of -¥1,321.56 in Q1 2024, compared to ¥86,306.83 in Q1 2023[23]